This article was originally published in The Tan Sheet
Executive SummaryBlistex President & CEO Richard Green elected 49th board chairman during association's annual executive conference in White Sulphur Springs, W.Va. May 16-19. A member of CHPA's board since 1994 and executive committee since 1997, Green is a 31-year veteran of Blistex. He succeeds outgoing chairman Michael Valentino, formerly Novartis Consumer Health Global Head OTC/Exec VP, who had to relinquish his chairmanship mid-term. CHPA members also affirm nominations of first-time board members Edward Kuehnle, Information Resources, Inc. North America group president, and Neill Walsdorf, president of Mission Pharmacal...
You may also be interested in...
The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.
Japanese companies agree to discontinue regenerative cell therapy pact after high-profile Phase II failure, but SanBio will move ahead with development and Dainippon will hold onto ex-partner stake for now.
Strides has set a sales target of $200-400m for Stelis’s generic injectables business in two to four years as part of its plan to reach $800m in total revenues in four years. Meanwhile, Stelis’s Rh-teriparatide for osteoporosis and sodium hyaluronate for osteoarthritis await Phase III incremental studies in the US.